SCHEMBL3425869

SCHEMBL3425869

O=C(NCc1ccc2[nH]ccc2c1)c1ccc(SC(F)(F)F)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.59
NR1H4 Q96RI1 2/20 0.59
PPARG P37231 2/20 0.50
NAMPT P43490 1/20 0.48
PTPRZ1 P23471 1/20 0.47
CACNA1G O43497 1/20 0.46
CACNA1H O95180 1/20 0.46
CACNA1I Q9P0X4 1/20 0.46
CHRNA7 P36544 3/20 0.46
KCNH2 Q12809 1/20 0.46
KLKB1 P03952 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
DRD5 P21918 1/20 0.43
MLYCD O95822 1/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3425821 0.91 EPHX2 (0.59) EPHX2NR1H4PPARGNAMPTPTPRZ1
SCHEMBL3425707 0.88 EPHX2 (0.47) EPHX2NR1H4PPARGNAMPTPTPRZ1
SCHEMBL3430846 0.86 CHRNA7 (0.58) EPHX2PPARGCACNA1GCACNA1HCACNA1I
SCHEMBL3401713 0.84 CACNA1G (0.46) EPHX2PPARGCACNA1GCACNA1HCACNA1I
SCHEMBL3429601 0.84 CACNA1G (0.49) EPHX2NR1H4PPARGPTPRZ1CACNA1G
SCHEMBL3427954 0.84 EPHX2 (0.46) EPHX2NR1H4PPARGNAMPTCACNA1G
SCHEMBL3424801 0.82 EPHX2 (0.54) EPHX2NR1H4NAMPTCHRNA7KLKB1
SCHEMBL3403207 0.82 ALDH1A1 (0.61) EPHX2NR1H4NPC1RAB9A
SCHEMBL3425693 0.82 EPHX2 (0.59) EPHX2NR1H4PPARGNAMPTCHRNA7
SCHEMBL3425854 0.81 NPC1 (0.56) EPHX2PPARGCACNA1GCACNA1HCACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101990537-A Amide derivatives as positive allosteric modulators and methods of use thereof ABBOTT LAB 2011-03-23 CN claimed
EP-2250162-A2 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF Abbott Laboratories (US) 2010-11-17 EP claimed
US-20090270408-A1 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-10-29 US claimed
WO-2009100294-A2 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-08-13 WO claimed
EP-2250162-B1 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF ABBVIE INC (US) 2014-03-19 EP disclosed
US-8536221-B2 Amide derivatives as positive allosteric modulators and methods of use thereof ABBVIE INC. (US) 2013-09-17 US disclosed
CN-101990537-A Amide derivatives as positive allosteric modulators and methods of use thereof ABBOTT LAB 2011-03-23 CN disclosed
EP-2250162-A2 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF Abbott Laboratories (US) 2010-11-17 EP disclosed
US-20090270408-A1 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-10-29 US disclosed
WO-2009100294-A2 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270408-A1 AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF CHRNA2, CHRNA4, CHRNA5 EPHX2 3581/4885NR1H4 1031/4885PPARG 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.